User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

Primary tabs

de Zeeuw, Dick Bekker, Pirow Henkel, Elena Hasslacher, Christopher Gouni-Berthold, Ioanna Jadoul, Michel [UCL]

Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk is related to residual albuminuria. We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addition to standard care, including ACE inhibitors or ARBs.

Document type Article de périodique (Journal article)
Publication date 2015
Language Anglais
Journal information "The lancet. Diabetes & endocrinology" - Vol. 3, no.9, p. 687-696 (2015)
Peer reviewed yes
e-issn 2213-8595
Publication status Publié
Affiliations UCL - SSS/IREC/NEFR - Pôle de Néphrologie
UCL - (SLuc) Service de néphrologie
Links
Bibliographic reference de Zeeuw, Dick ; Bekker, Pirow ; Henkel, Elena ; Hasslacher, Christopher ; Gouni-Berthold, Ioanna ; et. al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.. In: The lancet. Diabetes & endocrinology, Vol. 3, no.9, p. 687-696 (2015)
Permanent URL http://hdl.handle.net/2078.1/166640